RxDoctor Payments Data

Angela Peters, MD

Clinical Neurophysiology · Salt Lake City, UTNPI 1699076224

Payments from drug & device makers

$408,021in general payments, 2019–2025

Across 797 payments — averaging $511.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$295K
  • UCB SA$110K
  • DIXI Medical USA Corp$1K
  • Medtronic$626
  • SK Life Science, Inc.$454
  • UCB, Inc.$424
  • plus $566 from 4 others

What the payments were for

  • Consulting fees$3,25036%
  • Travel & lodging$2,12724%
  • Food & beverage$3,65940%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neuropace, Inc.760$294,634
UCB SA12$110,260
DIXI Medical USA Corp3$1,056
Medtronic6$626
SK Life Science, Inc.5$454
UCB, Inc.5$424
Cadwell Industries, Inc3$372
Greenwich Biosciences, Inc.1$85
Zimmer Biomet1$57
Livanova USA, Inc.1$53

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Utahto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$24,541
Medicare patients
111
Services billed
244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate213$263,207
AptiomEslicarbazepine Acetate29$74,408
Qudexy XrTopiramate12$41,805
LamictalLamotrigine25$18,425
Keppra XrLevetiracetam12$17,479
Lacosamide223$16,156
Tegretol XrCarbamazepine36$15,336
Clobazam164$12,778
Lamotrigine ErLamotrigine30$9,187
Levetiracetam214$6,112
Lamotrigine194$3,759
Rufinamide12$3,348
Clorazepate Dipotassium33$3,245
Zonisamide63$2,812
Topiramate139$2,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$454$263,207213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Utahon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Salt Lake City

Where these figures come from

Is this you, or does something look wrong? →